Pharming Group N.V [PHARM] vs Shell plc [SHELL] Detailed Stock Comparison

Pharming Group N.V.

EURONEXT
Loading...

Shell plc

EURONEXT
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Pharming Group N.V. wins in 2 metrics, Shell plc wins in 17 metrics, with 0 ties. Shell plc appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Pharming Group N.V. Shell plc Better
P/E Ratio (TTM) 57.15 14.90 Shell plc
Price-to-Book Ratio 4.31 1.47 Shell plc
Debt-to-Equity Ratio 41.78 43.17 Pharming Group N.V.
PEG Ratio 46.77 0.04 Shell plc
EV/EBITDA 23.94 5.49 Shell plc
Profit Margin (TTM) 0.76% 6.68% Shell plc
Operating Margin (TTM) 2.84% 8.44% Shell plc
EBITDA Margin (TTM) 2.84% 8.44% Shell plc
Return on Equity 1.02% 10.19% Shell plc
Return on Assets (TTM) 4.55% 4.92% Shell plc
Free Cash Flow (TTM) $53.95M $23.92B Shell plc
Dividend Yield N/A 3.71% N/A
1-Year Return -21.83% -7.07% Shell plc
Price-to-Sales Ratio (TTM) 2.71 0.80 Shell plc
Enterprise Value $810.05M $223.88B Shell plc
EV/Revenue Ratio 2.52 0.98 Shell plc
Gross Profit Margin (TTM) 80.19% 11.36% Pharming Group N.V.
Revenue per Share (TTM) $1 $45 Shell plc
Earnings per Share (Diluted) $0.00 $2.55 Shell plc
Beta (Stock Volatility) 0.12 -0.21 Shell plc

Pharming Group N.V. vs Shell plc Stock Performance Analysis

Loading Price Chart...

PHARM
SHELL

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Pharming Group N.V.-0.40%0.00%0.00%-21.28%-21.28%-21.28%
Shell plc-4.37%-4.73%-2.51%-12.81%-12.81%-12.81%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Pharming Group N.V.-21.83%-21.83%-21.83%-21.83%-21.83%-21.83%
Shell plc-7.07%-7.07%-7.07%-7.07%-7.07%-7.07%

Performance & Financial Health Analysis: Pharming Group N.V. vs Shell plc

MetricPHARMSHELL
Market Information
Market Cap i€1.02B€212.61B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i11,520,5765,859,028
90 Day Avg. Volume i12,234,8067,640,851
Last Close€1.11€35.68
52 Week Range€0.84 - €1.82€29.55 - €41.33
% from 52W High-38.94%-13.67%
All-Time High€459.55 (Jul 10, 2000)€41.15 (Apr 07, 2026)
% from All-Time High-99.76%-13.29%
Growth Metrics
Quarterly Revenue Growth0.15%-0.03%
Quarterly Earnings Growth0.86%3.46%
Financial Health
Profit Margin (TTM) i0.01%0.07%
Operating Margin (TTM) i0.03%0.08%
Return on Equity (TTM) i0.01%0.10%
Debt to Equity (MRQ) i41.7843.17
Cash & Liquidity
Book Value per Share (MRQ)€0.33€25.85
Cash per Share (MRQ)€0.26€5.34
Operating Cash Flow (TTM) i€46.72M€36.69B
Levered Free Cash Flow (TTM) i€58.63M€19.46B
Dividends
Last 12-Month Dividend Yield iN/A3.71%
Last 12-Month Dividend iN/A€1.25

Valuation & Enterprise Metrics Analysis: Pharming Group N.V. vs Shell plc

MetricPHARM (Apr 24, 2026)SHELL (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i57.1514.90
Forward P/E i46.7710.23
PEG Ratio i46.770.04
Price to Sales (TTM) i2.710.80
Price to Book (MRQ) i4.311.47
Market Capitalization
Market Capitalization i€1.02B€212.61B
Enterprise Value i€810.05M€223.88B
Enterprise Value Metrics
Enterprise to Revenue i2.520.98
Enterprise to EBITDA i23.945.49
Risk & Other Metrics
Beta i0.12-0.21
Book Value per Share (MRQ) i€0.33€25.85

Financial Statements Comparison: Pharming Group N.V. vs Shell plc

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPHARM (2025)SHELL (2025)
Revenue/Sales i376.13M266.89B
Cost of Goods Sold i45.50M224.39B
COGS % of Revenue i12.1%84.1%
Gross Profit i330.63M42.50B
Gross Margin i87.9%15.9%
Research & Development i100.37M1.17B
Operating Income (EBIT) i20.88M27.58B
Operating Margin i5.6%10.3%
EBITDA i36.28M53.40B
EBITDA Margin i9.6%20.0%
Pre-Tax Income i12.85M29.76B
Pre-Tax Income % of Revenue i3.4%11.1%
Income Tax i10.31M11.64B
Income Tax % of Revenue i2.7%4.4%
Net Income (Profit) i2.54M18.12B
Profit Margin i0.7%6.8%

Balance Sheet & Liquidity Metrics

MetricPHARM (2025)SHELL (2025)
Cash & Equivalents i145.31M29.63B
Total Current Assets i299.47M107.17B
Total Current Assets % of Revenue i79.6%40.2%
Total Current Liabilities i115.79M82.42B
Total Current Liabilities % of Revenue i30.8%30.9%
Long-Term Debt i107.07M66.52B
Long-Term Debt % of Revenue i28.5%24.9%
Total Shareholders Equity i277.10M175.32B
Retained Earnings i-272.98M153.53B
Retained Earnings % of Revenue i-72.6%57.5%
Property, Plant & Equipment i6.12M444.94B

Cash Flow Statement Comparison

MetricPHARM (2025)SHELL (2025)
Operating Cash Flow i47.47M35.46B
Operating Cash Flow % of Revenue i12.6%13.3%
Capital Expenditures iN/A1.15B
Free Cash Flow i53.95M23.92B
FCF Margin i14.3%9.0%
Debt Repayment i-4.25M-11.81B
Common Stock Repurchase iN/A-13.88B

Short Interest & Institutional Ownership Analysis

MetricPHARMSHELL
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i701.68M5.69B
Float Shares i690.78M5.52B
% Held by Insiders i1.89%0.06%
% Held by Institutions i20.99%35.30%
% Held by Public i77.12%64.64%

Dividend Analysis & Yield Comparison: Pharming Group N.V. vs Shell plc

MetricPHARMSHELL
Last 12-Month Dividend iN/A€1.25
Last 12-Month Dividend Yield iN/A3.71%
3-Year Avg Annual Dividend iN/A€1.19
3-Year Avg Dividend Yield iN/A0.95%
3-Year Total Dividends iN/A€3.57
Ex-Dividend DateN/AFeb 19, 2026